Cancer vaccines and Immunotherapy
Therapeutic drug delivery, i.e. various immunotherapies, including cancer vaccines, have been developed to improve clinical outcomes.
Prophylactic cancer vaccines
Currently, two prophylactic cancer vaccines are available: a vaccine to prevent malignancies caused by Hepatitis B (HepB) and a vaccine to prevent malignancies caused by the Human Papilloma Virus (HPV).
Read more in our HepB white paper and our HPV white paper.
Therapeutic cancer vaccines
Bacillus Calmette-Guérin (BCG) vaccine is commonly linked to prevention of Tuberculosis, but is also used to treat bladder cancer. Also, a dendritic cell-based vaccine (Sipuleucel-T) is commercially available for castration-resistant prostate cancer.
Additionally, several therapeutic cancer vaccines are in development or in the preclinical or clinical research phase.
Interested in our solutions?
Contact our commercial team!
Cell- and gene-based therapy
Therapeutic drug delivery can also be used to treat auto-immune diseases like Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA) using cell-based therapy. Indeed, intradermal administration of autologous dendritic cells to treat auto-immune diseases such as MS is being investigated.
However, for the treatment to be effective, it is important that viable and functional cells are not damaged by shear stress and reach the site of action without change in cell phenotype.
Idevax has an ongoing collaboration with the University of Antwerp (BE), University Hospital of Antwerp (BE) and Anicells (BE). The consortium is working on intradermal delivery of tolerogenic DC-based therapy to treat MS.
VAX-ID allowing reliable therapeutic drug delivery
A recent study showed that VAX-ID pre-configured with 32G, 27G or 26G needles can be considered a promising solution for reliable delivery of cell-based immunotherapy compared to regular injection methods.
Read more in our poster and stay tuned for more updates!